PREVENTION OF THROMBUS FORMATION AND GROWTH BY ANTITHROMBIN-III AND HEPARIN-COFACTOR-II DEPENDENT THROMBIN INHIBITORS - IMPORTANCE OF HEPARIN-COFACTOR-II

被引:22
作者
BUCHANAN, MR
LIAO, P
SMITH, LJ
OFOSU, FA
机构
[1] MCMASTER UNIV,DEPT SURG,HAMILTON L8S 4L8,ON,CANADA
[2] MCMASTER UNIV,DEPT PATHOL,HAMILTON,ON,CANADA
[3] CANADIAN RED CROSS SOC,BLOOD SERV,HAMILTON,ON,CANADA
基金
英国医学研究理事会;
关键词
ANTITHROMBIN III; HEPARIN COFACTOR II; THROMBUS FORMATION; THROMBUS GROWTH; SULODEXIDE; HEPARIN;
D O I
10.1016/0049-3848(94)90267-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heparin (HEP) prevents thrombus formation (TF) and thrombus growth (TG), by accelerating thrombin (THR) inhibition by antithrombin III (ATIII). Recent studies suggest that dermatan sulphate which catalyzes thrombin inhibition by heparin cofactor II (HCII), can inhibit TF and TG as effectively as HEP. This study compared the antithrombotic effects of HEP and another agent, Sulodexide (SLX) which catalyzes thrombin inhibition by ATIII and HCII simultaneously. TF was induced in rabbit jugular veins, using the stasis/hypercoagulation model. TG was measured as the accretion of I-125-fibrin onto existing thrombi in rabbit jugular veins. HEP and SLX inhibited TF when given in doses of 10 and 5 anti-thrombin U/kg, respectively. SLX (16 anti-thrombin U/kg or 260 mu g/kg) was more effective than HEP (120 antithrombin U/kg or 800 mu g/kg) in preventing TG when administered either as a bolus or by continuous infusion. These data suggest that agents which accelerate THR inhibition by both ATIII and HCII simultaneously can inhibit TF and TG with less systemic anticoagulation than comparable antithrombotic doses of HEP.
引用
收藏
页码:463 / 475
页数:13
相关论文
共 31 条
[1]  
AGNELLI G, 1992, THROMB HAEMOSTASIS, V67, P203
[2]   INFLUENCE OF HEPARIN TREATMENT ON BIOCHEMICAL MARKERS OF AN ACTIVATION OF THE COAGULATION SYSTEM [J].
AMELSBERG, A ;
ZURBORN, KH ;
GARTNER, U ;
KIEHNE, KH ;
PREUSSE, AK ;
BRUHN, HD .
THROMBOSIS RESEARCH, 1992, 66 (2-3) :121-131
[3]   BINDING OF THROMBIN TO SUBENDOTHELIAL EXTRACELLULAR-MATRIX - PROTECTION AND EXPRESSION OF FUNCTIONAL-PROPERTIES [J].
BARSHAVIT, R ;
ELDOR, A ;
VLODAVSKY, I .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (04) :1096-1104
[4]  
BOGATYYVER J, 1989, THROMB HAEMOSTASIS, V61, P538
[5]  
BOISCLAIR MD, 1993, IN PRESS THROMB HAEM, V69
[6]   EFFECTS OF HEPARIN, ITS LOW-MOLECULAR WEIGHT FRACTIONS AND OTHER GLYCOSAMINOGLYCANS ON THROMBUS GROWTH-INVIVO [J].
BONEU, B ;
BUCHANAN, MR ;
CADE, JF ;
VANRYN, J ;
FERNANDEZ, FF ;
OFOSU, FA ;
HIRSH, J .
THROMBOSIS RESEARCH, 1985, 40 (01) :81-89
[7]  
BRILLEDWARDS P, 1992, THROMB HAEMOSTASIS, V68, P424
[8]  
BRISTER SJ, 1993, THROMB HAEMOSTASIS, V69, P890
[9]  
BRISTER SJ, 1992, THROMB RES, V65, pS68
[10]  
BUCHANAN MR, 1985, BLOOD, V65, P198